Howe & Rusling Inc. Has $360,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Howe & Rusling Inc. boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after buying an additional 44 shares during the period. Howe & Rusling Inc.’s holdings in Regeneron Pharmaceuticals were worth $360,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Loomis Sayles & Co. L P lifted its holdings in shares of Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after acquiring an additional 393,997 shares during the period. NEOS Investment Management LLC raised its position in Regeneron Pharmaceuticals by 30.6% in the fourth quarter. NEOS Investment Management LLC now owns 17,650 shares of the biopharmaceutical company’s stock worth $12,573,000 after purchasing an additional 4,140 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in Regeneron Pharmaceuticals by 38.0% during the fourth quarter. UniSuper Management Pty Ltd now owns 7,306 shares of the biopharmaceutical company’s stock worth $5,204,000 after purchasing an additional 2,013 shares during the period. Sava Infond d.o.o. acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $492,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 7.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,008 shares of the biopharmaceutical company’s stock valued at $127,118,000 after purchasing an additional 12,757 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ REGN opened at $635.83 on Friday. The company’s 50 day simple moving average is $684.76 and its 200 day simple moving average is $803.87. The firm has a market capitalization of $69.51 billion, a P/E ratio of 16.61, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.55%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.